15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $7M | -$21M | 89.4% | -1601.1% | -$98M | — | $38M |
| 2024 | $26M | -$64M | 88.4% | -259.6% | -$61M | — | $29M |
| 2023 | $24M | -$66M | 88.5% | -295.4% | -$64M | — | $63M |
| 2022 | $15M | -$61M | 91.2% | -411.9% | -$50M | — | $39M |
| 2021 | $14M | -$110M | 100.0% | -794.4% | -$22M | — | $149M |
| 2020 | $14M | -$3M | 0.0% | -18.2% | -$13M | — | $4M |
| 2019 | $0 | -$23M | — | — | -$24M | — | $39M |
| 2018 | $20M | -$10M | 0.0% | -55.5% | -$6M | — | $63M |
| 2017 | — | -$21M | — | — | -$19M | — | $20M |
| 2016 | — | -$17M | — | — | -$137814 | — | $2M |
| 2015 | — | -$31440 | — | — | — | — | $5M |
| 2014 | — | -$30799 | — | — | — | — | $5263 |
| 2014 | — | -$193388 | — | — | — | — | $17868 |
| 2014 | — | -$186960 | — | — | — | — | $4568 |
| 2014 | — | -$180008 | — | — | — | — | $5883 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$22M | — | — | -$22M | — | $35M |
| Dec '25 | $0 | -$23M | — | — | -$17M | — | $38M |
| Sep '25 | $0 | -$18M | — | — | -$15M | — | $38M |
| Jun '25 | $0 | -$53M | — | — | -$53M | — | $145M |
| Mar '25 | $7M | $73M | 89.4% | -213.0% | -$12M | — | $228M |
| Dec '24 | $7M | -$18M | 89.1% | -261.8% | -$15M | — | $29M |
| Sep '24 | $7M | -$13M | 88.9% | -186.0% | -$16M | — | $31M |
| Jun '24 | $6M | -$15M | 87.4% | -252.2% | -$10M | — | $41M |
| Mar '24 | $5M | -$18M | 87.8% | -364.5% | -$20M | — | $54M |
| Dec '23 | $6M | -$16M | 85.3% | -280.0% | -$10M | — | $63M |
| Sep '23 | $6M | -$16M | 88.3% | -299.5% | -$13M | — | $69M |
| Jun '23 | $6M | -$18M | 89.4% | -315.1% | -$17M | — | $68M |
| Mar '23 | $6M | -$15M | 91.0% | -286.8% | -$23M | — | $34M |
| Dec '22 | $5M | -$14M | 95.8% | -296.0% | -$11M | — | $39M |
| Sep '22 | $4M | -$14M | 86.0% | -354.2% | -$8M | — | $135M |
| Jun '22 | $3M | -$18M | 90.1% | -534.2% | -$11M | — | $119M |
| Mar '22 | $2M | -$14M | 92.2% | -598.8% | -$19M | — | $130M |
| Dec '21 | $1M | -$16M | 100.0% | -1594.5% | -$12M | — | $149M |
| Sep '21 | $0 | -$87M | — | — | -$17M | — | $161M |
| Jun '21 | $0 | -$2M | — | — | — | — | $37M |
How the market has priced WHWK against its own fundamentals since 2025-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Whitehawk Therapeutics, Inc.'s revenue has declined 12.6% per year. These are computed facts, not advice.
As of FY2025, Whitehawk Therapeutics, Inc. reported — of total debt against $38M of cash.
In FY2025, gross margin was 89.4%, operating margin -1601.1%, and net margin -288.3%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.